Skip to main content

Table 1 Baseline characteristics of patients with RA in the TSUBAME study

From: Serum TNFα levels at 24 h after certolizumab pegol predict effectiveness at week 12 in patients with rheumatoid arthritis from TSUBAME study

Variables n = 100
Age (y) 58 (48–68)
Gender, n (% female) 82 (82.0%)
Disease duration (mo) 29 (8–84)
Stage (I/II/III/IV %) 40/48/6/6
Treatment history
 MTX use at baseline, n (%) 100 (100%)
  Dose, mg/w 14 (10–16)
 Glucocorticoid use at baseline, n (%) 8 (8%)
  Dose, mg/day 4.5 (2.0–7.0)
 bDMARDS naïve, n (%) 73 (73%)
Prior use of TNFi 18 (18%)
Prior use of Non-TNFi 6 (6%)
Prior use of both TNFi and non-TNFi 3 (3%)
28-tender joint count 8 (4–13)
28-swollen joint count 7 (3–11)
GH, VAS 0-100 mm 48 (26–70)
EGA, VAS 0-100 mm 40 (28–60)
Pain, VAS 0-100 mm 52 (28–72)
DAS28-ESR 5.4 ± 1.3
HAQ-DI 1 (0.5–1.5)
EQ-5D 0.6 (0.5–0.7)
CRP (mg/dl) 0.6 (0.1–2.1)
ESR (mm/h) 37 (21–68)
Rheumatoid factor (U/ml) 56.4 (21.1–129.1)
Anti-CCP antibody (U/ml) 95.0 (24.7–384.5)
MMP-3 (ng/ml) 87.3 (34.5–328)
  1. Data are mean ± SD, median (IQR), or number (%) of patients
  2. MTX methotrexate, bDMARDS biological disease-modifying anti-rheumatic drugs, TNFi TNFα inhibitor, GH VAS patient’s global assessment of disease activity visual analog scale, EGA VAS evaluator global assessment of disease activity visual analog scale, DAS disease activity score, HAQ-DI health assessment questionnaire disability index, EQ-5D EuroQol 5 Dimension, CRP C-reactive protein, ESR erythrocyte sedimentation rate, MMP-3 matrix metalloproteinase 3